全文获取类型
收费全文 | 5702篇 |
免费 | 533篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 40篇 |
儿科学 | 120篇 |
妇产科学 | 161篇 |
基础医学 | 932篇 |
口腔科学 | 67篇 |
临床医学 | 611篇 |
内科学 | 1007篇 |
皮肤病学 | 151篇 |
神经病学 | 761篇 |
特种医学 | 218篇 |
外科学 | 651篇 |
综合类 | 66篇 |
一般理论 | 4篇 |
预防医学 | 648篇 |
眼科学 | 188篇 |
药学 | 350篇 |
中国医学 | 5篇 |
肿瘤学 | 267篇 |
出版年
2023年 | 30篇 |
2022年 | 53篇 |
2021年 | 108篇 |
2020年 | 68篇 |
2019年 | 107篇 |
2018年 | 116篇 |
2017年 | 115篇 |
2016年 | 114篇 |
2015年 | 139篇 |
2014年 | 154篇 |
2013年 | 250篇 |
2012年 | 372篇 |
2011年 | 354篇 |
2010年 | 223篇 |
2009年 | 180篇 |
2008年 | 309篇 |
2007年 | 311篇 |
2006年 | 269篇 |
2005年 | 323篇 |
2004年 | 283篇 |
2003年 | 267篇 |
2002年 | 255篇 |
2001年 | 128篇 |
2000年 | 110篇 |
1999年 | 121篇 |
1998年 | 77篇 |
1997年 | 54篇 |
1996年 | 62篇 |
1995年 | 60篇 |
1994年 | 50篇 |
1993年 | 44篇 |
1992年 | 86篇 |
1991年 | 84篇 |
1990年 | 56篇 |
1989年 | 64篇 |
1988年 | 68篇 |
1987年 | 70篇 |
1986年 | 65篇 |
1985年 | 50篇 |
1984年 | 38篇 |
1983年 | 33篇 |
1982年 | 28篇 |
1981年 | 32篇 |
1980年 | 30篇 |
1979年 | 45篇 |
1975年 | 27篇 |
1973年 | 30篇 |
1972年 | 26篇 |
1971年 | 30篇 |
1969年 | 25篇 |
排序方式: 共有6247条查询结果,搜索用时 15 毫秒
1.
Judith Brock Andreas Schmid Thomas Karrasch Petra Pfefferle Jutta Schlegel Inga Busse Annette Hauenschild Barbara Schmidt Maria Koukou Efthymia Arapogianni Andreas Schultz Miriam Thomalla Secil Akinci Johannes Kruse Winfried Padberg Andreas Schffler Jens Albrecht 《Clinical endocrinology》2019,91(3):400-410
2.
3.
4.
Noninvasive Intracranial Cerebral Flow Velocity Evaluation in the Emergency Department by Emergency Physicians 总被引:2,自引:0,他引:2
Michael Shafé MD Michael Blaivas MD RDMS Edmond Hooker MD Leigh Straus BS 《Academic emergency medicine》2004,11(7):774-777
Transcranial Doppler (TCD) is an accepted modality for the evaluation of cerebral blood flow velocities. OBJECTIVES: The purpose of this study was to test the feasibility of bedside TCD measurement in the emergency department (ED) with critically ill, intubated patients. METHODS: A prospective convenience sample of patients presenting to a university hospital over a two-month period underwent TCD evaluation of the middle cerebral artery. Intubated patients with head trauma and any patient requiring tracheal intubation were eligible. A 2-MHz Doppler probe was positioned over the temporal bone to acquire blood flow velocities. An emergency medicine resident and research assistant obtained measurements. Continuous TCD tracings were recorded on a video cassette recorder tape for quality assurance review and data collection. Vital signs and therapeutic interventions were also recorded. Flow velocities were measured in cm/s; the peak Resistance Index (RI) was calculated for each patient. RESULTS: A total of 30 patients were enrolled in the study. Adequate tracings were obtained in 25 patients (83%) without a disruption of resuscitation. Tracings could not be obtained in five patients; they were listed as TCD failures. However, in two of these patients, adequate flow velocity tracings were obtained after resuscitation. Four patients were evaluated during tracheal intubation. One patient was monitored successfully during cardiopulmonary resuscitation. The median time required for data acquisition was 1.9 minutes. The mean highest RI for those who expired was 0.84. For those who survived, the mean highest RI was 0.52. The difference of 0.32 was statistically significant (p = 0.04). CONCLUSIONS: Noninvasive blood flow velocity monitoring of the middle cerebral artery using TCD is feasible in the ED when performed at the bedside on intubated patients with traumatic brain injury and others during tracheal intubation and resuscitation. 相似文献
5.
We conducted a randomized, double-blind, crossover trial of two anticholinergic agents--trihexyphenidyl and tridihexethyl chloride (a quaternary anticholinergic that does not cross the blood-brain barrier)--in patients with acquired nystagmus and measured visual acuity and nystagmus before and at the end of 1 month on each medication. Of the 10 patients admitted to the study, only five completed trials of both drugs due to intolerance of medication or intercurrent illness. Of six patients who completed the trial of trihexyphenidyl, only one showed improvement. Of six patients who completed a trial of tridihexethyl chloride, four showed improvement. We conclude that (1) trihexyphenidyl is not a reliable treatment for acquired nystagmus, although occasional patients may benefit; (2) anticholinergic agents may suppress nystagmus by peripheral rather than central mechanisms; and (3) the side effects of anticholinergic agents limit their effectiveness in the treatment of nystagmus. 相似文献
6.
M F Matangi J A Strickland J J Burgess E F Busse 《The Canadian journal of cardiology》1987,3(7):342-344
Operative mortality, postoperative morbidity and follow up data were analyzed retrospectively from 122 consecutive patients, over 65 years old undergoing elective aortocoronary bypass grafting for symptomatic relief of angina pectoris at the Plains Health Centre, Regina, Saskatchewan, from January 1980 to December 1985. There were two in-hospital deaths (operative mortality 1.6%). Definite perioperative myocardial infarction occurred in 12 patients (9.8%). The 120 survivors were followed for a mean of 32 months. There were three deaths during follow-up, giving a five-year probability of survival of 93%. Twenty-three clinical events (including deaths) occurred during follow-up, giving a five-year probability of event free survival of 72%. Ninety percent of patients say they are pleased with their operation. Seventy-eight percent are currently angina free. These data illustrate the effectiveness of aortocoronary bypass grafting in low risk elderly patients with symptomatic coronary artery disease. 相似文献
7.
8.
9.
10.
M J Buxton S D Sullivan L F Andersson C J Lamm B Liljas W W Busse S Pedersen K B Weiss 《The European respiratory journal》2004,24(4):568-574
Early intervention with budesonide is an effective strategy for mild persistent asthma, which has been shown to provide additional clinical benefits at a low incremental cost using USA cost data. The present authors analysed whether this strategy would be cost-effective using cost data for other countries. Based on the 3-yr prospective, randomised, double-blind inhaled Steroid Treatment As Regular Therapy (START) in early asthma study (comparing budesonide and placebo combined with usual asthma therapy), the cost-effectiveness was estimated separately for eight different countries, from both healthcare payer and societal perspectives, of adding budesonide to usual asthma therapy. Local unit costs were applied to data for the total trial population. Incremental cost-effectiveness ratios (ICER) were estimated as cost per symptom-free day (SFD) gained. Budesonide increased SFDs by an average of 14.1 days annually. From a healthcare payer perspective, budesonide would reduce the total cost of asthma care in Australia. In Sweden, Canada, France, Spain, UK, China and the USA, the ICER ranged from US$2.4-11.3 per SFD. From a societal perspective, budesonide would be cost-saving in Australia, Canada and Sweden. In conclusion, for countries where costs with budesonide are higher, the policy implication has to be determined by that health system's willingness to pay for an additional symptom-free day. However, where budesonide therapy increases symptom-free days and reduces total costs, the policy conclusion clearly favours early intervention. 相似文献